Articles On Phylogica (ASX:PYC)

PYC starts human trials for PYC-001 to treat rare eye disease OncoSil device successfully treats first patient in Türkiye, enabling tumour removal    PYC to start human trials for rare eye disease PYC Therapeutics (ASX:PYC) has received a...

Canaccord rates PYC a Buy with a target price of $0.22, possibly rising to $1.20 PYC is advancing RNA-based treatments for rare genetic diseases Trial results expected in 2024/25, with potential market launch by 2028  Canaccord Genuity ha...

The ASX200 closed up 0.46% at 7,813 points, as the market continues to recoup last weeks losses. The Information Technology sector climbed 2% higher in the wake of a solid Friday session on Wall Street, followed closely by Discretionary...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record another solid gain. At the time of writing, the benchmark index is up 0.5% to 7,816.4 points. Four ASX shares that have failed to follow the market higher today...

Tryptamine’s psilocybin trial indicates potential for treating fibromyalgia Actinogen says Xanamem eases depression but misses cognitive goals PYC reports vision gains using experimental eye drug   Tryptamine’s Phase 2a trial shows promis...

The ASX 200 dropped over 3% on Monday amid recession fears and weak US data Over $100 billion was wiped off the Aussie market in two days Global markets fell sharply, while safe-haven assets like gold and the yen gained   The ASX 200 inde...

PYC’s VP-001 improves vision in ongoing eye disease trials LTR Pharma’s Spontan is now available for treating erectile dysfunction under TGA’s program   PYC’s drug shows promise in eye disease trials PYC Therapeutics (ASX:PYC) has provide...

Western Australia wanting to diversity beyond resources and become a global leader in health and medical life sciences Cook Government to invest $16m into driving a connected and innovative ecosystem for WA’s health and medical research se...

Biotechnology company PYC Therapeutics Ltd (ASX:PYC) has begun a follow-up study in the United States to assess the efficacy and safety of its drug candidate VP-001 to treat patients with blinding eye disease Retinitis Pigmentosa type 11 (R...

Imricor completes installation of iCMR capital equipment at Lausanne University Hospital in Switzerland PYC Therapeutics says safety data from patient cohort four successfully reviewed with recommendation trial continues Cynata Therapeutic...

For biotech investors, the news of an approval by the US FDA is a genuinely exciting milestone. The FDA is the ultimate gatekeeper for the US pharmaceutical market, which is by far the world’s largest. Approval from the FDA not only validat...

The ASX200 closed the day up, about half a per cent, leading up to the King’s birthday public holiday long weekend. The Consumer Discretionary sector was the strongest, up nearly 1.2% on news global central banks are dropping interest ra...

The ASX200 is trading above expectations, up 0.35%. The discretionary sector leads the way, up 1.1%. Utilities is up just short of a per cent. IT, on the other end, has taken the biggest hit, down around 0.4% Biotechnology company PYC...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. In afternoon trade, the benchmark index is up 0.4% to 7,853.5 points. Four ASX shares that are rising more than most today are listed below. Here's why...

07 Jun 2024 - A snapshot of the stocks on the move, featuring PYC Therapeutics (ASX:PYC), Caprice Resources (ASX:CRS) and Walkabout Resources (ASX:WKT).

  To register for today's webinar click here. PYC Therapeutics (ASX:PYC) announces that their fourth drug candidate for PhelanMcDermid Syndrome (PMS) is effective in human brain cells. The company announces that it has been able to restore...

PYC Therapeutics (ASX: PYC) has made a breakthrough with its main drug candidate for the potential treatment of neurodevelopmental disorder Phelan-McDermid Syndrome (PMS). New studies by PYC have found it can restore the deficient protein t...

Biotechnology company Pyc Therapeutics Ltd (ASX:PYC) has announced that it has been able to restore a deficient protein causing neurodevelopmental disorder Phelan McDermid Syndrome (or PMS), as part of Pyc’s wider drug development program w...

Investors with a high risk tolerance might want to consider adding the two ASX penny stocks in this article to a balanced portfolio. That's because although they are high risk investments, they have the potential to offer high rewards. Let'...

It has been a tough finish to the week for the S&P/ASX 200 Index (ASX: XJO). In afternoon trade, the benchmark index is down 1.2% to 7,719 points. Four ASX shares that are not letting that hold them back are listed below. Here's why t...

PYC Therapeutics gets FDA approval PYC Therapeutics (ASX:PYC) has received an Orphan Drug Designation (ODD) from the US FDA for its drug candidate, PYC-001, aimed at treating OPA1-associated vision loss. The ODD is a special designation giv...

It can be useful for investors to keep an eye on which shares have experienced meaningful insider buying. This is because insider buying is often regarded as a bullish indicator, as few people know a company and its intrinsic value better t...

The S&P/ASX 200 Index (ASX: XJO) is having a day to remember on Thursday. In afternoon trade, the benchmark index is up a sizeable 1.55% to 7,873.9 points. Four ASX shares that have failed to follow the market higher today are listed b...

PYC Therapeutics (ASX:PYC) has announced that it has completed dosing in patient cohort 4 (75 μg dose) of the ongoing Single Ascending Dose study. 

PYC Therapeutics (ASX:PYC) says that one of its candidates for a blinding eye disease of childhood called Autosomal Dominant Optic Atrophy has demonstrated disease-modifying potential in ‘retina in a dish’ models.

The ASX200 closed the day up more than a per cent (1.08%). All sectors bar one finished in the green. Energy fell 1.5 per cent, but Healthcare lead gains, nearly two per cent (1.97%). Telecommunications followed, up 1.7 per cent. In t...

The ASX200 is up nearly a per cent – in a harmonious flow with futures predictions. Every sector – aside from energy – is in the green. Materials and industrials are having a particularly strong run, both up around 1.5 per cent.  I...

PYC Therapeutics (ASX:PYC) has completed Dose Range Finding (DRF) studies for its investigational drug, PYC-003, in Non-Human Primates (NHPs). The company’s PYC-003 drug is designed to address Autosomal Dominant Polycystic Kidney Diseas...

It’s been three consecutive months that US inflation data has come in higher than expected and, with that, predictions around interest rate cuts have been pushed back from July to November. Inflation rose from 3.2 per cent in February to...

PYC Therapeutics (ASX:PYC) has announced the successful closure of the institutional component of the entitlement offer to raise up to approximately $74.6 million. 

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.39% to 7,763.70. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotify...

PYC Therapeutics (ASX:PYC) has announced the results of a study conducted in three-dimensional human models derived from patients with end-stage renal failure due to autosomal dominant polycystic kidney disease.

PYC has developed a new drug candidate for the >5 million people worldwide[1] with Polycystic Kidney Disease (PKD) This drug candidate has demonstrated efficacy in human models derived from the kidneys of patients with end-stage renal f...

4DX surges more than 50pc after an update from the US PYC Therapeutic said its fourth drug candidate could be effective in kidney disease Pro Medicus has just signed a $20m, eight-year contract in the US   4D Medical up over 50pc Medtech...

PYC Therapeutics (ASX:PYC) has held a pre-IND meeting with the US FDA and announced it has agreed on a proposed pathway through clinical trials for its second investigational candidate.

PYC to take ADOA drug to human clinical trials Imugene provides update of its Phase 1 MAST (Metastatic Advanced Solid Tumours) trial Cleo’s CleoDX Triage Test was published in ‘Cancer’ journal   PYC to commence human trials in 2024 after...

PYC Therapeutics (ASX:PYC) has announced that the Safety Review Committee (SRC) governing one of its phase 1 clinical trials has approved the escalation of dosing to patient cohort 2.

PYC Therapeutics (ASX:PYC) has completed dosing for patients in cohort one of the Platypus clinical trial.

ASX to open higher despite a drop on Wall Street Tonight’s US CPI data weighs on markets These two drugs could be the top selling drugs in history   The ASX 200 is set to open slightly higher on Thursday despite stocks falling in New York...

PYC receives Fast Track designation from the US FDA BCAL Diagnostics announces breakthrough results Nova Eye reports strong sales of iTrack Advance in the US   PYC Therapeutics granted Fast Track from US FDA Genetic diseases specialist PY...

PYC Therapeutics to advance to Phase 2 clinical trial Osteopore announced new CEO and non-executive director Incannex has as engaged Fortrea to manage its Phase 2/3 clinical trial   PYC to advance to Phase 2 after toxicology tests RNA dru...

PYC Therapeutics (PYC) doses the first patient with drug candidate VP-001, designed to treat blinding eye disease, Retinitis Pigmentosa Type 11 (RP11) The drug candidate is part of a phase one Single Ascending Dose study to assess the sa...

ASX falls 0.17% ahead of Chalmers dropping The Budget on the nation Financials led the pack today, adding 0.5% on an otherwise fairly moribund day Voltaic Strategic Resources climbs 188% on pre-assay lithium results at Ti Tree   The ASX h...

CardieX jumps 16pc after getting FDA clearance for CONNEQT Pulse CONNEQT Pulse is a world first multi-use vascular biometric monitor  Three ASX biotechs received clearance to commence studies   Health devices and wearables tech company Ca...

PYC Pharmaceuticals (PYC) lands approval from the US FDA to begin human trials of a new drug to treat the blinding eye disease Retinitis Pigmentosa (RP11) The genetic disease affects around one in every 100,000 people, and no other treat...

Rhythm plunged 45% this morning after announcing some TGA news The FDA has cleared PYC Therapeutics for first ever human trial on Retinitis Pigmentosa Type 11   Rhythm Biosciences (ASX: RHY) crashed 47% this morning after withdrawing its...

Sonic has taken a stake in Microba Immutep enters into second deal with Merck (Germany) and Pfizer  ImpediMed has a new CEO   Sonic takes strategic stake in Microba Giant healthcare stock Sonic Healthcare (ASX:SHL) has bought a stake in s...

PYC Therapeutics (PYC) completes single-dose toxicology of its investigational Retinitis Pigmentosa type 11 (RP11) treatment drug candidateAccording to PYC, the studies proved the drug was safe and well-tolerated at all dose levels assessed...

Highlights: The ASX 200 benchmark index closed up today, gaining 0.41% to end at 6,496.20 points. Over the last five days, the index has lost 4.56% and has shed 12.03% over the last 52 weeks. Materials was the best performing sector,...

PYC Therapeutics (PYC) adds a third drug program for the treatment of Phelan McDermid Syndrome (PMS) to its clinical pipelineThis new program follows in-vitro test results of PYC’s RNA therapeutic demonstrating an ability to correct the fau...